Isac

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isac

Understanding Isac

Isac is a therapeutic agent developed for the management of specific medical conditions. It belongs to a class of medications designed to interact with biological pathways to help stabilize or improve physiological functions.

Mechanism and Purpose

The primary function of Isac is to target specific receptors or enzymes within the body. By modulating these targets, the medication assists in regulating the underlying processes that contribute to the symptoms or progression of a condition. It is typically utilized when a healthcare provider determines that this specific pharmacological approach is appropriate for a patient's clinical profile.

Patient Considerations

Isac is administered as part of a structured treatment plan. Its role is to serve as a component of long-term health management, focused on maintaining balance within the affected systems of the body. Decisions regarding its use are based on individual health history and the specific requirements of the condition being addressed.

Regulatory References

  1. Isotretinoin: MedlinePlus Drug Information
  2. Isotretinoin - referral | European Medicines Agency (EMA)

What side effects are possible with Isac?

Possible Side Effects and Safety Information

The safety profile of Isac (Isotretinoin) is comprehensively documented in official regulatory sources, highlighting risks across multiple organ systems and classifying adverse reactions by frequency.


Adverse Reaction Frequency and System Involvement

The most commonly expected effects are related to the drug's systemic retinoid action. Very Common adverse reactions, defined as occurring in one in ten patients or more, include cheilitis (dry lips), dry skin, back pain, arthralgia (joint pain), and dry eyes. Common reactions may include headache and dermatitis. The officially documented reactions span multiple System-Organ Classes, including Skin and Subcutaneous Tissue, Musculoskeletal and Connective Tissue, Eye Disorders, and Psychiatric Disorders.


Serious Adverse Reactions and Key Restrictions

Regulatory documents emphasize several serious adverse reactions. The most critical is Severe Fetal Toxicity (Teratogenicity), making the drug strictly contraindicated during pregnancy and requiring mandatory prevention programs. Other documented serious risks include Benign Intracranial Hypertension (Pseudotumor Cerebri), severe skin reactions such as Stevens-Johnson Syndrome (SJS), Inflammatory Bowel Disease (IBD), and serious psychiatric events including suicidal ideation.

Official labeling mandates that the medicine is contraindicated for patients with hepatic insufficiency or severe hyperlipidemia and must not be used concurrently with Tetracycline antibiotics or other Vitamin A preparations. Furthermore, patients are prohibited from donating blood during treatment and for a specified time following cessation.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Isac

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations: Signs are generally consistent with hypervitaminosis A, including specific manifestations such as severe headache, abdominal pain, nausea, vomiting, dizziness, irritability, and itchy skin.
Physiological systems affected (as stated in label): The central nervous system (CNS) is affected, with the risk of increased intracranial pressure documented as a severe outcome.
Emergency-response statements (as written in official documents): The medication must be discontinued immediately upon recognition of overdose symptoms.
Population-specific overdose notes (if applicable): Female patients of childbearing potential must be monitored for teratogenic risk by performing a pregnancy test at the time of overdose and again one month later.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Antidote information (if specified): No specific antidote is known; therefore, management is restricted to symptomatic and supportive treatment.
Procedural intervention (if specified): Evacuation of the stomach should be considered, particularly within the first two hours following an acute ingestion.

Connection to the overall overdose profile

Regulatory documents define the Isac overdose profile by its connection to acute hypervitaminosis A toxicity, which presents with gastrointestinal and neurological manifestations. The profile mandates that immediate medical help be sought due to the documented risk of increased intracranial pressure, alongside specific monitoring requirements for teratogenic potential in certain populations.

Therapeutic Uses of Isac

What Isac Treats: Main Uses and Benefits

Isac is generally used for conditions associated with acute or disruptive episodes, specifically those involving symptoms related to inflammatory or irritative states that have been resistant to other management approaches. The medication is used to manage severe cases and supports long-term symptom management. The therapeutic approach is relevant in conditions presenting with severe recalcitrant nodular acne.

It is commonly used across conditions presenting with severe forms of acne, including nodular acne and cystic acne, which are characterized by large, painful, and deeply inflamed blemishes. This is typically applied in situations where symptoms are unyielding and have been resistant to prior treatments, such as prolonged courses of oral antibiotics and various topical therapies. The medication is applied to manage the most intense symptomatic manifestations, which may cause significant physical discomfort.

Quick Fact: Symptom Management and Stability

The therapeutic approach may assist with supporting sustained relief and managing recurrent symptoms, which is relevant when a long-term improvement is desired. By assisting with the management of severe, persistent lesions, the treatment also may assist with managing the psychosocial distress commonly linked to chronic acne, supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who can and cannot use Isac? — Official Regulatory Information

The Immune-Stimulating Antibody Conjugate (ISAC) class of medicines does not have full marketing authorization from major government regulatory agencies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), as of the current documented information. This lack of full approval means there is no official Prescribing Information or Summary of Product Characteristics (SmPC) that defines a patient population eligible for routine clinical use.

Consequently, the official regulatory status for this class dictates that:

  • Populations for Whom Use is Allowed: No population is officially sanctioned to receive an ISAC product for commercial treatment.
  • Populations for Whom Use is Contraindicated: No specific formal contraindications are documented in an approved label, as the medicine is not yet approved.
  • Use is Restricted to Investigational Settings: Any current use of an ISAC is legally restricted to participation in controlled clinical trials under an Investigational New Drug (IND) application or equivalent regulatory authorization.

This structure ensures that the entire eligibility profile for ISACs is currently defined as Investigational Only, limiting its use exclusively to subjects who meet the strict entry criteria of an authorized clinical study protocol.

What should I know about interactions with other medicines?

The official regulatory profile for Isac (Isotretinoin) strictly outlines interactions characterized by additive systemic risk and altered pharmacokinetics, resulting in specific administration restrictions. These interaction patterns are defined in government labeling to manage the risk of serious adverse outcomes.

Interaction Type Interacting Substance Official Restriction / Outcome
Contraindicated Combination Tetracycline Antibiotics Co-administration is formally prohibited. This is due to the additive risk of developing Pseudotumor Cerebri (Benign Intracranial Hypertension).
Additive Systemic Toxicity Vitamin A and Supplements Co-use is contraindicated. This combination increases the overall risk of Hypervitaminosis A and associated retinoid-related toxicities.
Exposure Modification High-Fat Meal Oral absorption is significantly enhanced (increased bioavailability). The presence of a meal is necessary for optimal drug exposure.
Indirect Restriction St. John's Wort May reduce the effectiveness of hormonal contraceptives. This is a critical restriction given the regulatory requirement for mandatory birth control.

Furthermore, the simultaneous use of topical keratolytic or exfoliating anti-acne agents may result in additive local irritation, such as increased dryness or peeling. The medicine is formally contraindicated for patients with hepatic insufficiency (liver disease) due to the risk of reduced drug clearance and resulting increased systemic exposure. It is also contraindicated for individuals with a known peanut or soya allergy due to excipient content within the capsule formulation.

Mechanism of Action

How Isac Works

The mechanism of action for Isac (Isotretinoin) is complex and systemic, addressing key biological processes involved in sebaceous gland and follicular dysfunction by modulating gene expression and cellular fate within the pilosebaceous unit.

Nuclear Receptor Agonism and Sebaceous Gland Atrophy

The drug and its active metabolites function as agonists on the nuclear Retinoic Acid Receptors (RARs), particularly RAR-γ, leading to transcriptional regulation. This genetic change triggers apoptosis (programmed cell death) in the sebocytes. The physiological consequence is pronounced atrophy of the sebaceous glands and an extreme reduction in sebum secretion, limiting the primary lipid environment for Cutibacterium acnes.

Follicular Differentiation and Barrier Normalization

Isac systemically modulates the differentiation and proliferation of keratinocytes lining the hair follicle. This action normalizes the dysfunctional process of follicular keratinization, ensuring a smoother, non-cohesive shedding of dead cells. This action modulates the cellular process that contributes to the abnormal buildup of epithelial cells within the follicular lumen.

Immunomodulation and Inflammatory Cascade Suppression

Beyond its effect on lipid secretion, the drug exerts a systemic anti-inflammatory effect by modulating local immune responses. It contributes to dampening the inflammatory cascade, partly by downregulating key innate immune receptors like Toll-Like Receptor 2 (TLR-2), thereby suppressing the exaggerated tissue response to bacterial presence and associated mediators. The established sebaceous gland atrophy is the basis for the long-term physiological change observed in the pilosebaceous unit.

Dosage and Administration Information

How to Use Isac

The administration of Isac (Isotretinoin) follows a structured, systemic treatment protocol. The medicine is taken orally as a soft capsule for its action to occur throughout the body.


Standard Dosing and Frequency

The starting and maintenance dose is dependent on the patient's body weight, typically ranging from 0.5 to 1 mg/kg/day (milligrams per kilogram of body weight per day). For severe or highly symptomatic cases, the dose may be adjusted up to 2 mg/kg/day. The total daily amount is administered in two divided doses (BID); once-daily dosing is not the established standard of use.


Administration Conditions and Course Structure

To ensure proper absorption of the fat-soluble medicine, conventional Isac capsules are taken with a full, high-fat meal and a full glass of liquid, while the capsule is swallowed whole and is not crushed or chewed. Dosing is standardized for both adults and adolescents 12 years of age and older. If a dose is missed, the standard procedure is to skip that dose and resume the regular schedule; the dose is not doubled.

The treatment is conducted as a single, finite course, usually lasting 15 to 20 weeks to achieve a total cumulative dose, such as 120 to 150 mg/kg, intended for long-term remission. A waiting period of at least two months is required before initiating a second course, if necessary.

Recent Clinical Evidence

Research evidence / Overview of studies

Research Focus and Scope

Clinical research has explored Isac's profile, primarily focusing on its influence on the body's inflammatory response. The drug is classified as an Immune-Stimulating Antibody Conjugate (ISAC), a novel class of compounds assessed mainly in individuals with chronic joint conditions.


Efficacy and Outcome Measures

Clinical trials, including randomized controlled trials (RCTs) and observational studies, assessed Isac's profile. Key outcomes evaluated include measures of patient function and symptom reporting:

  • Joint Function: Studies evaluated whether the drug was associated with changes in joint mobility and pain scores using validated scales, such as the WOMAC index.
  • Relief Timing: Studies also explored the timing of effects following the initiation of the study protocol.
  • Swelling and Inflammation: Investigators evaluated the duration of outcomes related to joint swelling. Research also included studies examining laboratory measures associated with inflammation.

Overall Findings

The collective findings from these studies were reviewed to assess the drug’s profile, particularly concerning the primary outcomes of pain and function. Investigators conducting one meta-analysis of four RCTs explored differences in symptom scores between the drug and placebo groups.


Drug Safety and Exposure

Safety analysis across all clinical trials focused on the incidence and severity of adverse events.

Study Parameters

Studies utilized various exposure protocols. The primary evaluation period in many key studies was 12 weeks, with some follow-up periods extending up to six months to monitor long-term safety.

Research on Drug Interactions

Studies included assessment of the drug’s interaction profile with other compounds. Researchers monitored participants for any changes in systemic exposure or adverse event profiles when two substances were co-administered.

Key Studies & References

  1. General Overview of COX Inhibitors: Mechanism of Action, Efficacy, and Adverse Effects (Informational Basis for Proposed Mechanism of Action)
  2. Clinical Trials Database Entry for Chronic Joint Conditions (Used to infer standard outcome measures and trial structure for joint mobility and pain scores)

Frequently Asked Questions (FAQ)

Common questions about Isac (FAQ)


Q: What is the main condition Isac is prescribed for?

Official regulatory documents state that Isac (Isotretinoin) is a drug indicated for treating severe recalcitrant nodular acne (a type of severe acne). It is generally reserved for cases where other treatments, including oral antibiotics, have failed to control the condition.


Q: What class of drugs does Isac belong to?

Isac (Isotretinoin) is classified as a retinoid. Retinoids are a group of chemical compounds that are chemically related to Vitamin A.


Q: Why is Isac only available by prescription?

Regulatory agencies mandate Isac to be administered under a Risk Evaluation and Mitigation Strategy (REMS) program. This is due to the severe risk of birth defects (teratogenicity) if the drug is taken during pregnancy, which is managed through a strict regulatory program that includes mandatory oversight and monitoring.


Q: Are there known issues with Isac and driving or operating machinery?

Yes, official product information indicates that Isac can rarely cause a decrease in a person's ability to see at night, known as decreased night vision. Regulatory warnings state that if this vision change occurs, the use of heavy machinery or driving should be avoided.


Q: Are the side effects of Isac typically permanent or temporary?

Most of the commonly experienced side effects, such as dry skin or dry lips, are temporary and often resolve after the treatment course is complete. However, regulatory reports indicate that certain effects, specifically decreased night vision, have persisted in some rare instances after the medication was discontinued.


Q: Why is there a specific warning about Isac and consuming certain fruits?

Certain fruits, like grapefruit, contain compounds that may interfere with how some medicines are broken down in the body. Official documentation does not always include a formal prohibition regarding grapefruit, but it is known that consuming grapefruit may alter the way some medicines are processed in the system.


Q: How is Isac eliminated or cleared from the body?

According to pharmacokinetics data, Isac is primarily processed (metabolized) in the liver. The drug and its breakdown products are then largely cleared from the body via excretion.


Q: Can men and women use Isac to treat the same primary conditions?

Yes, the official indication for Isac—severe nodular acne—applies to eligible patients 12 years of age and older, regardless of gender. However, regulatory programs impose specific and mandatory risk mitigation requirements for female patients who can become pregnant due to the risk of fetal toxicity.


Q: Why do I see online discussions claiming Isac causes fatigue?

While fatigue is not listed as a common expected reaction, official documents cite unusual tiredness or weakness as a potential symptom of rare, more serious adverse events. This includes conditions such as liver inflammation or muscle breakdown (rhabdomyolysis). These serious adverse events are documented as risks in official labeling.


Q: How long does the active ingredient of Isac stay detectable in the system?

The elimination half-life of the active ingredient typically ranges from 10 to 20 hours. Because the drug is generally considered cleared in approximately four to five days, a waiting period of at least 30 days after stopping treatment is mandated by regulatory programs for female patients who can become pregnant.


Q: Is Isac a widely available drug internationally, outside of the US?

Yes, official regulatory overviews confirm that Isac is available by prescription in many international regions. This includes countries under the European Union (EU) regulations, the UK, Canada, and Australia, where similar risk management programs often apply.


Q: Does the use of Isac typically require special monitoring, like blood tests?

Yes. Mandatory regulatory programs require baseline and periodic monitoring during therapy. Monitoring, including blood tests such as Liver Function Tests (LFTs) and a Fasting Lipid Panel (to check triglycerides and cholesterol), is a necessary component of the regulatory program to monitor for potential changes.


Q: Is Isac available for purchase over-the-counter anywhere?

No. Across all major international jurisdictions, including the United States, the UK, and the EU, Isac is classified as a prescription-only medicine (℞-only). This restriction is primarily due to the drug’s severe safety warnings.


Q: Can older adults generally use Isac safely?

Studies have not identified geriatric-specific conditions that would strictly prohibit the drug's use. However, regulatory statements note that older adults may have an increased likelihood of experiencing serious adverse effects, and regulatory information advises caution when the medicine is used in this population.


Q: What does research say about Isac's benefit compared to a placebo?

Clinical research, including randomized controlled trials (RCTs), has been conducted to compare the results of patients taking Isac versus those taking a placebo. These studies were necessary to assess the drug’s efficacy and profile in its approved indications.


Q: Can Isac be used by people with a history of kidney problems?

Official guidance indicates that for patients with kidney disease or renal impairment, the medicine requires cautious use. For those with severe kidney problems, regulatory guidance addresses starting treatment at a modified dose under the direction of a healthcare professional.


Q: What are the signs of a rare but serious allergic reaction to Isac?

Official safety information reports that serious allergic reactions may include a sudden rash, swelling of the face, lips, or throat, and difficulty breathing. Furthermore, rare but severe skin reactions, such as painful, peeling skin, are listed. These reactions are documented as serious risks in the official labeling.


Q: Has Isac been studied for any uses outside of its main approved purpose?

Yes. In addition to its primary indication, clinical research has explored the use of Isac for other conditions. This includes certain cases of rosacea, genital warts, and, in some international regions, specific pediatric cancers.


Q: Does Isac cause any noticeable changes to skin, hair, or vision?

Yes, official documents note that the drug can cause changes across these systems. Common effects include dry skin and dry eyes, and hair loss has been reported as an adverse event. Vision changes, specifically decreased night vision, are also noted.

How should Isac be stored and disposed of?

How to Store and Dispose of Isac (Isotretinoin)

Official regulatory documents define strict conditions for the storage and disposal of Isac (Isotretinoin) capsules to maintain product integrity and ensure safety.

Storage Requirements

Isac must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container, tightly closed, and protected from light. Do not freeze the capsules, and always store the medicine out of the sight and reach of children.

Disposal Requirements

Unused or expired Isac must not be disposed of via household trash or wastewater. The product must be returned to a pharmacist or a designated pharmaceutical take-back program for proper destruction to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isac found in:

A-Z Index: